Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
The Ulman Foundation, a longstanding staple in the community, recently held a ribbon-cutting for its new brick "Legacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback